0IGA Stock Overview
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Emergent BioSolutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.00 |
| 52 Week High | US$15.10 |
| 52 Week Low | US$1.48 |
| Beta | 1.57 |
| 11 Month Change | 8.70% |
| 3 Month Change | 21.99% |
| 1 Year Change | 348.43% |
| 33 Year Change | -76.26% |
| 5 Year Change | -81.33% |
| Change since IPO | -80.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IGA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 5.5% | 4.1% | 1.7% |
| 1Y | 348.4% | -14.2% | 9.0% |
Return vs Industry: 0IGA exceeded the UK Biotechs industry which returned -15.4% over the past year.
Return vs Market: 0IGA exceeded the UK Market which returned 9% over the past year.
Price Volatility
| 0IGA volatility | |
|---|---|
| 0IGA Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IGA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IGA's weekly volatility has decreased from 24% to 15% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,600 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
Emergent BioSolutions Inc. Fundamentals Summary
| 0IGA fundamental statistics | |
|---|---|
| Market cap | US$547.80m |
| Earnings (TTM) | -US$208.80m |
| Revenue (TTM) | US$1.13b |
0.5x
P/S Ratio-2.6x
P/E RatioIs 0IGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IGA income statement (TTM) | |
|---|---|
| Revenue | US$1.13b |
| Cost of Revenue | US$835.20m |
| Gross Profit | US$290.30m |
| Other Expenses | US$499.10m |
| Earnings | -US$208.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.85 |
| Gross Margin | 25.79% |
| Net Profit Margin | -18.55% |
| Debt/Equity Ratio | 130.3% |
How did 0IGA perform over the long term?
See historical performance and comparison